A new standard in prenatal testing is about to be born…

The challenge

Millions of babies are born every year with severe genetic diseases.
Existing non-invasive screening methods allow the detection of less than 10% of known genetic disorders. Invasive genetic tests are risky, late, and thus rarely used.

Solution

1

 

2

 

3

 

Cell free DNA is circulating in maternal blood
IdentifAI’s technology enables the isolation, examination and analysis of the fetus’s cell free DNA
IdentifAI’s novel paradigm and digital solutions allow early, non-invasive and comprehensive prenatal genetic testing

Technology

IdentifAI’s cutting edge bioinformatics technology offers an early and comprehensive prenatal screening test for genetic syndromes. Using a simple blood test from the mother during the first trimester of the pregnancy, our proprietary data science algorithms provide a high-resolution yet comprehensive perspective of the fetus’s health at an early stage of the pregnancy.

How does it work?

1. A blood draw is taken from the mother

2. The sample is sequenced – fetal and maternal DNAs are still mixed
3. Fetus’s DNA is digitally isolated using IdentifAI’s computational process
4. Fetus’s DNA is reconstructed at high resolution, and actionable variants (mutations) are located and analyzed
5. A genetic report is generated

Current solutions

Current technologies are either invasive, e.g. amniotic fluid test, or limited to only ~10% of genetic conditions, mainly chromosomal abnormalities.

Detect chromosomal conditions

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23

Our solution

IdentifAI’s technology offers the only available clinical solution for an early, non-invasive and comprehensive prenatal genetic screening, from point mutations to chromosomal anomalies.

A decade of deep academic research

Retrospective clinical validation with Rabin medical center

IP portfolio covering basic technology, algorithms and implementations (US, EU, China)

Two IIA grants, Seed investment.

Proof-of-concept demonstrated

Strategic partnerships with key players

Prospective clinical study with 3 leading medical centers

About Us

AMIR BEKER PhD

CEO
PhD in Medical Physics, a graduate of IDF's "Talpiot" program; held an R&D post in the IAF; a managing partner in Pamot VC fund. Founder and CEO of BSP (TASE:BSP). Co-founder of GistMD. A member of 8400 Health Network.

PROF. NOAM SHOMRON PhD

CSO
Head of the Functional Genomics Lab at Tel Aviv University’s Medical School. Director of the Djerassi Institute of Oncology. Co-founder of several Biotech companies

TOM RABINOWITZ MD PhD

CTO
MD PhD in computational genomics, specifically in detection of diseases through advanced algorithms and AI. For his work, he won several prizes, scholarships and awards.

NOA LISCOVITCH PhD

Head of Research
PhD in Computational neuro-genomics with expertise in genome engineering and NGS data analysis. Led impactful projects published in top-tier journals. Winner of highly competitive prizes and grants during post-doctoral studies at NYU and NYGC.

OREN TADMOR

Head of Product
Technological leader and manager of multi-disciplinary teams. 25 years experience in IAF as large-scale technological projects manager and F-16 squadron commander. Experience as EIR in Venture Studio ShizimVS. B Sc. Electrical Engineering.

RAVIT MESIKA

Data Scientist
Data Scientist specializing in Machine Learning and Deep Learning algorithms. Experienced in developing end-to-end data pipelines tailored for various business models. MSc in Biochemistry with expertise in Bioinformatics and Neuroscience. Won the Polek prize and several other awards.

SAPIR BORNSTEIN

Product Analyst
Product analyst focusing on market research,genetic data pre-processing and R&D support.B.Sc. in Biomedical Engineering, special interests includecomputational genomics and systems biology.

ROTEM SHOMRAT CPA

CFO
Rotem has more than 10 years of experience in accounting firms, High-Tech & communication industry. Prior to this position, she has worked in the finance team of Nice Systems, a global NASDAQ traded company, and other private fast-growing companies.

YOSSI BORNSTEIN

Chairman
CEO and the founder of Shizim Group. Has played key roles in the Israeli & International biomed industry. Former General Manager of Bristol-Myers Squibb (Israel). Co-Founder & Director of Microbot Medical (NASDAQ: MBOT) and XACT Robotics. Director of Can-Fite BioPharma (NASDAQ: CANF).

Collaborators

Contact Us